These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3629327)

  • 21. Procainamide-induced pseudo-obstruction in a diabetic patient.
    Peterson AM; Conrad SD; Bell JM
    DICP; 1991 Dec; 25(12):1334-5. PubMed ID: 1815428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Procainamide-induced agranulocytosis and thrombocytopenia.
    Rothman IK; Amorosi EL
    Arch Intern Med; 1979 Feb; 139(2):246-7. PubMed ID: 434983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Agranulocytosis during combined procainamide and phenytoin therapy.
    Crook JE; Woosley RL; Leftwich RB; Natelson EA
    South Med J; 1979 Dec; 72(12):1599-601. PubMed ID: 515773
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thrombocytopenia following sustained-release procainamide.
    Meisner DJ; Carlson RJ; Gottlieb AJ
    Arch Intern Med; 1985 Apr; 145(4):700-2. PubMed ID: 2580499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Severe transient pancytopenia associated with procainamide ingestion.
    Bluming AZ; Plotkin D; Rosen P; Thiessen AR
    JAMA; 1976 Nov; 236(22):2520-1. PubMed ID: 1036516
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical use of sustained-release procainamide in treatment of cardiac arrhythmias.
    Michelson EL; McGeehin FC; Levin BK
    Angiology; 1988 Jul; 39(7 Pt 2):647-54. PubMed ID: 3044199
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Procainamide-induced agranulocytosis differs serologically and clinically from procainamide-induced lupus.
    Starkebaum G; Kenyon CM; Simrell CR; Creamer JI; Rubin RL
    Clin Immunol Immunopathol; 1996 Feb; 78(2):112-9. PubMed ID: 8625553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversible severe anaemia and granulocytopenia caused by procainamide. A case report.
    van Beek RJ; Bieger R; den Ottolander GJ
    Scand J Haematol; 1978 Aug; 21(2):150-2. PubMed ID: 694426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative bioequivalence and efficacy of two sustained-release procainamide formulations in patients with cardiac arrhythmias.
    Hilleman DE; Patterson AJ; Mohiuddin SM; Ortmeier BG; Destache CJ
    Drug Intell Clin Pharm; 1988; 22(7-8):554-8. PubMed ID: 2458219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Procainamide-induced agranulocytosis: report of two cases and review.
    Nagesh KG; Poulose KP; Tseng TH; Schadchehr A
    J Kans Med Soc; 1980 Jan; 81(1):18-24. PubMed ID: 6153211
    [No Abstract]   [Full Text] [Related]  

  • 31. Sustained-release procainamide: use of serum concentrations to determine dosage.
    Reed WE; Cooper MW
    South Med J; 1985 Oct; 78(10):1190-3. PubMed ID: 4049036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sustained release procainamide in patients with myocardial infarction.
    Birkhead J; Evans T; Mumford P; Martinez E; Jewitt D
    Br Heart J; 1976 Jan; 38(1):77-80. PubMed ID: 1252299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A pharmacokinetic comparison of two sustained-release oral procainamide preparations.
    Hore P; Bones P; Rollinson T; Ikram H
    Br J Clin Pharmacol; 1979 Sep; 8(3):267-71. PubMed ID: 497093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Agranulocytosis caused by procainamide (Pronestyl)].
    Hensen A
    Ned Tijdschr Geneeskd; 1974 Apr; 118(17):624-5. PubMed ID: 4133296
    [No Abstract]   [Full Text] [Related]  

  • 35. Antiarrhythmic and hemodynamic evaluation of indecainide and procainamide in nonsustained ventricular tachycardia.
    Pratt CM; Francis MJ; Seals AA; Zoghbi W; Young JB
    Am J Cardiol; 1990 Jul; 66(1):68-74. PubMed ID: 2193498
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Procainamide induced agranulocytosis].
    Rollag A
    Tidsskr Nor Laegeforen; 1982 Jan; 102(2):96-7. PubMed ID: 7101253
    [No Abstract]   [Full Text] [Related]  

  • 37. Agranulocytosis, procainamide, and phenytoin.
    Fleet S
    Ann Intern Med; 1984 Apr; 100(4):616-7. PubMed ID: 6703561
    [No Abstract]   [Full Text] [Related]  

  • 38. Septic complications of procainamide-induced agranulocytosis: report of two cases.
    Freed JS; Reiner MA
    Mt Sinai J Med; 1988 Mar; 55(2):194-7. PubMed ID: 3290673
    [No Abstract]   [Full Text] [Related]  

  • 39. Efficacy of a new sustained release procainamide preparation: evaluation with 24-hour Holter monitoring.
    Garcia JR; Godley ML; Freedman RJ
    J La State Med Soc; 1982; 134(1):8-9. PubMed ID: 7086265
    [No Abstract]   [Full Text] [Related]  

  • 40. Desensitization to procainamide.
    Ream CR; Barrera R
    J Med Soc N J; 1970 Mar; 67(3):107-10. PubMed ID: 5264623
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.